• Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing

CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company’s investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth.

The event will highlight Emergent’s commitment to strengthening domestic manufacturing capabilities, supporting public health preparedness and creating opportunities for skilled jobs in Massachusetts. Emergent plans to add approximately 50 manufacturing, technical and operational positions as part of its investment in the site.

Emergent’s investment supports growth in Massachusetts’ biotechnology sector while helping build a skilled workforce for the future of advanced manufacturing.

Media Coverage Information
Following the ceremony, media will have the opportunity to speak with company representatives.

Speakers

  • Joe Papa, president and chief executive officer, Emergent
  • Bill Hartzel, senior vice president, manufacturing and bioservices, Emergent
  • Secretary Eric Paley, secretary, executive office of economic development
  • Senator Paul Feeney, Massachusetts Senate
  • Representative William Galvin, Massachusetts House of Representatives

Date/Time
Wednesday, September 16 at 10:00 am ET 

Please arrive no later than 9:45 a.m. to allow time for security screening.

Address
Emergent Canton
90 Shawmut Road, Canton, MA 02021 

Visuals

  • Ceremonial ribbon cutting
  • Executive remarks
  • Group photos with company and state leaders

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Media RSVP:
Alicia Conners
Senior Director, Corporate Communications
mediarelations@ebsi.com

MONTRÉAL, Sept. 15, 2026 (GLOBE NEWSWIRE) — Morocco Strategic Minerals Corporation. (TSXV: MCC) (“Morocco Strategic Minerals” or the “Company”) announces new surface rock sampling results from the Tamdghoust exploration permit, located north of the historical Aït Zekri mine within its Western High Atlas portfolio in Morocco. The results identify gold-bearing quartz veins, locally associated with significant silver and copper mineralization, expanding the Company’s gold exploration targets beyond the historical drilling footprint at Aït Zekri. 

New Gold Occurrences North of Aït Zekri

The Company’s recent surface sampling program, consisting of 48 grab samples, has extended the known mineralized trend by approximately 2,800 metres along strike. The newly identified occurrences display geological characteristics similar to those observed at the Aït Zekri mine. At Aït Zekri, gold mineralization is associated with quartz veining and sulphides hosted within pelitic rocks and calcareous sandstones, with local brecciation and alteration. These results materially expand the prospective footprint and support the interpretation of a broader mineralized trend extending northward from Aït Zekri. 

*Further geological mapping, systematic sampling and drilling will be required to establish the continuity, geometry and extent of mineralization along this trend.

Gold assay highlights include:

  • 2.57 g/t Au in sample TM-GB-0006;
  • 2.33 g/t Au in sample TM-GB-0016;
  • 1.68 g/t Au in sample TM-GB-0010;
  • 1.37 g/t Au in sample TM-GB-0021; and
  • 0.80 g/t Au in sample TM-GB-0022.

Gold values in the analyzed sample series ranged from below 0.05 g/t Au to 2.57 g/t Au, with 14 out of the 48 samples returning grades greater than 0.20 g/t Au, highlighting the widespread occurrence of gold mineralization within the sampled quartz-vein system.

2026_09_15_Figure_1_Drillhole samples

Figure 1: Drillhole and surface samples location at Ait Zekri licence et Tamdghoust permit

In addition to the gold results, the sampling program returned notable copper and silver values from several locations across the permit.

Copper and associated silver highlights include:

  • 4.27% Cu and 193 g/t Ag in sample TM-GB-0049;
  • 2.57% Cu and 88 g/t Ag in sample TM-GB-0048; and
  • 1.69% Cu and 57 g/t Ag in sample TM-GB-0005.

Additional notable silver results include:

  • 143 g/t Ag in sample TM-GB-0008;
  • 121 g/t Ag in sample TM-GB-0050;
  • 95 g/t Ag in sample TM-GB-0017;
  • 78 g/t Ag in sample TM-GB-0016;
  • 69 g/t Ag in sample TM-GB-0019;
  • 62 g/t Ag in sample TM-GB-0018;
  • 62 g/t Ag in sample TM-GB-0021; and
  • 56 g/t Ag in sample TM-GB-0045.

The distribution of gold, copper and silver values across multiple sampling locations provides additional targets for follow-up exploration and supports further geological and structural evaluation of the mineralized vein system across the Tamdghoust permit.

Quartz-vein-hosted mineralization observed at Tamdghoust.: Quartz-vein-hosted mineralization observed at Tamdghoust.

A Media Snippet accompanying this announcement is available by clicking on this link.

Quartz-vein-hosted mineralization observed at Tamdghoust.

Aït Zekri: Historical Drilling and Geological Context

A recent compilation by GoldMinds Geoservices incorporates 18 historical diamond drill holes totalling approximately 2,018.6 metres, with assay information available for a significant portion of the drilling. The historical drill-hole data, gold assays and AZ-GB surface samples have been integrated into a preliminary three-dimensional geological model to evaluate the relationship between surface mineralization and the zones intersected at depth. 

Historical drilling highlights include: 

  • SAZ-12: 1.94 g/t Au over 5.00 metres from a downhole depth of 43.70 metres, including 6.48 g/t Au over 1.00 metre;
  • SAZ-13: 1.99 g/t Au over 6.00 metres from a downhole depth of 65.30 metres;
  • SAZ-17: 2.85 g/t Au over 2.00 metres from a downhole depth of 81.50 metres, including 5.06 g/t Au over 1.00 metre;
  • SAZ-6: 1.84 g/t Au over 3.10 metres from a downhole depth of 54.20 metres; and
  • SAZ-13: 0.86 g/t Au over 6.30 metres from a downhole depth of 52.00 metres.

*Reported intervals are downhole lengths and do not necessarily represent true widths.

The deepest mineralization identified to date was intersected in hole SAZ-9 at approximately 180 metres below surface, highlighting the significant vertical extent of the Aït Zekri mineralized system, which remains open for further evaluation along strike and at depth. The combined surface and drill-hole dataset highlights several important characteristics of the Aït Zekri target, where gold mineralization has been identified both in multiple historical drill holes and in surface rock samples. Gold values at surface occur along the same broader prospective trend as the drilled mineralization, supporting the interpretation of a potentially continuous mineralized system. The presence of mineralization from surface to depth provides additional potential for vertical extension. 

2026_09_15_Figure_3_Section View

Figure 3: Section view of the Ait Zekri exploration area showing historical SAZ diamond drill holes, gold-bearing drill intervals.

Advancing Toward Drilling Across the High Atlas Portfolio

Across its Western High Atlas portfolio, the Company is accelerating preparations for exploration and resource-definition drilling on priority targets. Its permanent field team is advancing geological and technical work in parallel with applications for drilling authorizations and coordination with specialized contractors.

Site preparation includes cleaning and rehabilitation of historical mine workings, pumping of flooded levels, stability and safety assessments, and preparation of access for field crews and drilling equipment. These activities are being coordinated with the geological work to support the safe and efficient advancement of the planned programs.

Drilling will aim to better define the geometry, continuity and grade distribution of priority mineralized structures and collect the data needed to support a potential future mineral resource estimate. The Company is targeting the commencement of initial drilling before the end of 2026, subject to the required authorizations, completion of preparatory work and contractor availability. 

“The Tamadghoust results broaden the gold exploration opportunity north of Aït Zekri and add copper and silver targets to our follow-up program” said Pierre-Olivier Goulet, Chief Executive Officer. “Historical drilling provides an important foundation for understanding the mineralized system, while our surface work is identifying additional areas to evaluate. Across the High Atlas portfolio, our focus is on advancing the strongest targets toward drilling, with geological work, permitting, contractor coordination and site preparation progressing in parallel.”

Analytical Methods

All samples were submitted to the African Laboratory for Mining and Environment (Afrilab) in Marrakech, Morocco. Samples were analyzed for silver, copper, iron, lead and zinc using aqua regia digestion with an atomic absorption spectroscopy finish. Samples containing greater than 5% Cu were reanalyzed using titration, and gold was assayed by fire assay.

The Company’s QA/QC program includes the insertion of certified reference materials, blank samples and duplicate samples within the sample stream. Quality-control results are reviewed by the Company’s independent Qualified Person before analytical results are approved for public disclosure. 

Stock Option Grants

The Corporation also announces the grant, effective September 15, 2026, of an aggregate of 4,920,000 stock options to directors, officers and members of its team. Each option entitles the holder to acquire one common share of the Company at an exercise price of C$0.25 for a term of five years. These stock options are granted in accordance with the terms of the stock option plan of the Corporation.

Qualified Person

The scientific and technical information in this release has been approved by Merouane Rachidi, Ph.D., P.Geo., an independent Qualified Person as defined by National Instrument 43-101.

Contact Information

Pierre-Olivier Goulet
President and Chief Executive Officer
Email: info@moroccosm.com
TEL: 1-579-476-7000

Forward-Looking Statements and Disclaimer

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding geological and structural interpretations; the potential orientation, continuity and extent of mineralization; the identification, evaluation and prioritization of exploration and drill targets; additional geological and technical work, including mapping, sampling and three-dimensional modelling; the rehabilitation, dewatering and access of historical mine workings; the timing and commencement of drilling; the receipt of required authorizations; contractor availability; the potential results of future exploration and drilling programs; the potential definition of mineralized structures and their geometry, continuity and grade distribution; the collection of data to support a potential future mineral resource estimate; and the exploration and development potential of the Company’s Western High Atlas portfolio.

Generally, forward-looking information can be identified by terminology such as “plans”, “expects”, “intends”, “targets”, “may”, “will”, “could”, “should”, “potential”, or variations of such words and phrases. Forward-looking information is based on the Company’s estimates, expectations and assumptions as of the date of this release and is subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied.

Readers should not place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise such information except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0c987719-15df-487b-b06b-5f4154acd143
https://www.globenewswire.com/NewsRoom/AttachmentNg/f1e846de-8010-4068-85a4-270d4b60a3a7

This press release was published by a CLEAR® Verified individual.

Cohen, a prominent figure in the global business and national security arenas, who currently serves as a strategic advisor to SoftBank, a global leader in investments in artificial intelligence infrastructure and semiconductors, will help shape QXL’s technological and commercial roadmap in quantum computing, software, and quantum sensing. 

TEL AVIV, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (Nasdaq: QXL) (“Quantum X Labs” or the “Company”), today announced the appointment of Mr. Yossi Cohen, former Director of the Mossad and a leading figure in Israel’s national security community, as President of the Company’s Scientific Advisory Board.

Mr. Cohen will work alongside the Scientific Advisory Board’s existing members – including Prof. Oren Kurland of the Technion – Israel Institute of Technology and Prof. Oren Raz of the Weizmann Institute of Science – to strengthen QXL’s strategic direction across quantum computing, quantum error correction, quantum software for clinical trials, quantum cybersecurity and quantum sensing with a strategic focus on expanding the scale of the Company’s operations and commercializing its quantum technologies, particularly for the defense, aerospace, homeland security, and critical infrastructure markets.

Cohen served as Director of the Mossad from 2016 to 2021, following his tenure as Israel’s National Security Advisor from 2013 to 2016 and as Deputy Director of the Mossad. During a 38-year career in intelligence and national security, he oversaw some of Israel’s most significant covert operations, including the acquisition of Iran’s nuclear archive in 2018, as well as efforts that helped lay the groundwork for the Abraham Accords. This operational and strategic background is directly relevant to QXL’s work in GPS-denied navigation, precision timing, quantum-secured communications, and technologies designed to operate in contested electromagnetic environments.

Since leaving public service, Cohen has operated at the intersection of national security and global technology investments. In 2021, he joined SoftBank to lead the company’s activities in Israel Vision Fund 2, helping identify and support growth-stage technology companies. In this capacity, he was involved in SoftBank’s Israeli cybersecurity investments, including investments related to Wiz, Claroty, and Cato Networks.

In August 2026, Yossi Cohen was appointed a strategic advisor to SoftBank. This role brings him closer to the group’s senior decision-making centers and expands his areas of activity to include the financing and development of artificial intelligence infrastructure and cloud data centers, as well as investments in semiconductor companies serving these infrastructures — an area increasingly overlapping with quantum sensing chips, high-performance computing, and next-generation secure infrastructure.

The appointment is intended to connect QXL’s scientific program with the strategic, commercial and security realities in which quantum technologies will be adopted. QXL’s portfolio includes a neutral-atom quantum computing platform; an AI-driven quantum error-correction architecture; Quantum Gyro, which is developing quantum-based gyroscope chip technology for highly precise, jamming-resistant navigation in GPS-denied environments; next-generation atomic clocks for precision timing; and initiatives in quantum cybersecurity, nuclear simulations, and life sciences.

Yaki Baranes, Co-Chief Executive Officer, Quantum X Labs:

“There are very few people who have operated at the heart of national security systems at the highest level and then moved into the inner circle of one of the world’s most important technology investors. That combination is rare.

We did not appoint Yossi Cohen to be an honorary name on our letterhead. We appointed him because Quantum X Labs is developing a range of unique capabilities — including quantum sensing for navigation and timing, a quantum error-correction decoder, and quantum cybersecurity — that will be tested in the real world, not only in the laboratory.”

Yossi Cohen, President of the Scientific Advisory Board:

“I am honored to chair the Scientific Advisory Board. After evaluating several companies across deep-tech and quantum technology landscape, I chose to join Quantum X Labs because I found a rare combination of exceptional human capital and significant technological potential. My years in senior leadership roles, including at the Mossad, taught me to recognize the unique combination of people, technology, and vision needed to create meaningful impact. I see that combination at Quantum X Labs.

I look forward to working with the Company’s management and scientific team as it continues to develop and advance its technology portfolio — from academic research to reality.”

Cohen’s new appointment at SoftBank is particularly relevant to QXL’s development trajectory in hardware and infrastructure. SoftBank’s broader strategy includes large-scale AI computing, data center capacity, and exposure to the semiconductor sector — including through the group’s historical holding in Arm, one of the world’s leading semiconductor intellectual property companies.

QXL’s work in quantum gyroscope chips, precision timing devices, and error-corrected computing systems lies precisely at the intersection of chips, sensing, secure communications, and high-performance computing – areas that global investors increasingly view as strategic infrastructure.

The Scientific Advisory Board provides strategic scientific guidance, reviews and validates the Company’s technological direction, and helps align QXL’s roadmap with developments in quantum science, engineering, and dual-use applications.

As President of the Board, Cohen will help prioritize, at the board level, applications in defense and critical infrastructure, advance international partnerships, and translate QXL’s intellectual property – including its work in error correction through the integration of AI and quantum technologies, as well as its portfolio of sensing technologies — into government and operational programs and commercial channels.

Quantum X Labs Inc.

 Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. isfocused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected impact of Mr. Cohen’s appointment as President of the Scientific Advisory Board; the Company’s strategic direction, technological roadmap and growth initiatives; the development, advancement and commercialization of its quantum computing, quantum error-correction, quantum software, quantum sensing and quantum cybersecurity technologies; the potential applications of its technologies in the defense, aerospace, homeland security and critical infrastructure markets; the expansion of the Company’s operations; the pursuit and development of international partnerships; the translation of the Company’s intellectual property and technology portfolio into governmental, operational and commercial programs and channels; and the expected market opportunities for the Company’s products and technologies. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites.

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com

Expanded ANT coverage and the integrated 3D geological model combine 1,637 drillholes, 1,707 multi-element samples, structural geology and property-scale geophysics across approximately 70 km²

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) (the “Company” or “ESGold”) is pleased to announce the completion of its expanded Phase 2 Ambient Noise Tomography (“ANT-2”) survey and an updated property-scale three-dimensional (“3D”) geological model for the Company’s Montauban Project, located approximately 120 kilometres west of Québec City, Québec.

ANT-2 substantially expands geophysical coverage northward from the original ANT-1 survey area and is now integrated with ESGold’s historical drilling, lithology, structural interpretation, assay data, regional mapping, and multi-element geochemistry. Developed by Geomatic World Inc. using Leapfrog Geo and incorporating ANT interpretations completed by CAUR Technologies Inc., the updated model establishes a broader property-scale framework for geological interpretation and exploration targeting.

Highlights

  • The integrated 3D model significantly expands ESGold’s exploration framework beyond the historic mine area, tracing favourable geological units toward the east and southeast while identifying deeper structural corridors and new exploration opportunities laterally and at depth.
  • The southern and eastern corridors have emerged as priority exploration areas where favourable lithology, structural architecture, geochemical pathfinders and supporting geophysical features converge.
  • ANT-2 used 200 three-component geophone stations to substantially expand geophysical coverage northward from the original ANT-1 survey area, with the resulting model providing useful geological constraint from approximately 86 metres to about 1.2 kilometres below surface.
  • The integrated geological interpretation now covers approximately 70 km² across the Montauban Project.
  • The consolidated geological database contains 1,637 drillholes, including 90 additional historical holes recently incorporated into the model, together with 1,707 regional multi-element ICP samples, while the northern ANT-2 area remains comparatively under-tested.

Expanded ANT-2 Survey

CAUR Technologies Inc. completed the expanded ANT-2 survey across the northern portion of the Montauban Project. The campaign deployed 200 three-component geophone stations at an average spacing of approximately 400 to 600 metres. The stations continuously recorded ambient seismic noise for 32 days between March 19 and April 19, 2026. ANT is a fully passive geophysical method requiring no active seismic source; the resulting data was used to generate a three-dimensional shear-wave velocity model evaluated across 1,251 grid nodes.

Expanded Ambient Noise Tomography (ANT) Survey Coverage at the Montauban Project
Figure 1: Expanded Ambient Noise Tomography (ANT) Survey Coverage at the Montauban Project. The original ANT-1 survey area is shown in blue hatching, while the completed ANT-2 survey substantially expands geophysical coverage northward across the broader Montauban property. Black triangles identify 90 additional historical drill holes incorporated into the updated geological model.

The ANT-2 model provides useful geological constraint from approximately 86 metres to about 1.2 kilometres below surface. The interpretation identifies broad near-horizontal low-velocity layers and narrower near-vertical low-velocity corridors trending approximately 020°. These features have been integrated into the property-scale 3D geological model to support structural interpretation and exploration targeting.

Property-Scale Exploration Targeting

The updated model integrates the expanded ANT interpretation with 1,637 drillholes, 1,707 regional multi-element ICP samples, lithology, historical assays, structural interpretation and regional mapping. The integrated interpretation of the model supports the concept of Montauban being a gold and silver rich volcanogenic massive sulphide (“VMS”) system where structural controls have strongly influenced the current mineralized geometry.

Geological Interpretation and Exploration Implications

The integrated model provides ESGold with a significantly broader view of Montauban, allowing the Company to evaluate the project as a larger mineralizing system rather than simply a series of historically mined lenses. The known Au-Ag-rich VMS mineralization occurs within a structurally complex environment where folding, faulting and deformation may have displaced, repeated or stacked favourable geological units and mineralized horizons.

ANT identifies two important geological features:

  • broad near-horizontal low-velocity layers that may help define major lithological packages; and
  • near-vertical corridors trending approximately 020° that provide a framework for evaluating deeper structural controls and potential extensions of the broader geological system.

These ANT features are not interpreted as mineralization on their own. Their exploration significance increases substantially where they coincide with favourable geology, known mineralized trends, historical drilling and Zn, Cu, Ba and Ag geochemical pathfinders.

The updated model has highlighted several areas of particular exploration interest:

  • South: favourable geological units and modeled mineralized shells can now be evaluated beyond the historic workings.
  • East and southeast: geological units associated with known Montauban mineralization can be traced into less-explored areas, where structural trends and geochemical responses provide compelling vectors for follow-up.
  • North: the expanded ANT-2 area represents a large, comparatively under-tested exploration domain where additional integration of historical drilling, geophysics and geochemistry may generate further targets.

Importantly, the combination of favourable lithology, deep structural corridors, geochemical pathfinders and supporting geophysical responses provides ESGold with a growing pipeline of testable exploration opportunities extending both laterally and at depth. While the model does not demonstrate continuity of mineralization into these areas, it materially strengthens the Company’s ability to identify where additional mineralized zones may occur within the broader Montauban system.

“Completing ANT-2 and integrating it with our historical drilling, geochemistry and geological data gives us a much stronger framework for how we evaluate the broader Montauban property,” said Gordon Robb, Chief Executive Officer and Director of ESGold. “We now have a property-scale model that allows us to systematically rank opportunities and make more informed decisions about where we deploy exploration capital. With drilling already underway around the historic mine area, this work provides the foundation to expand our exploration focus across a much larger portion of the property.”

“For the first time, we have a three-dimensional framework that allows us to follow the geological units associated with the known mineralization farther to the east while simultaneously tracing the deeper fault and structural system beneath Montauban. This is particularly important because deformation may have displaced, folded or repeated favourable horizons, creating exploration opportunities that would not necessarily be apparent from the historical surface geology and shallow drilling alone. The geological significance of this work is that Montauban can now be evaluated as a three-dimensional mineralizing system rather than simply as a collection of historical workings and individual mineralized lenses,” said André Gauthier, Geological Engineer and Director of ESGold. “In a deformed Au-Ag-rich VMS environment, the key exploration question is not simply whether a geophysical anomaly exists, but whether favourable lithology, structural architecture, geochemical vectors and geophysical observations converge in the same volume of rock. The integrated model gives us a much stronger basis to test for extensions, repetitions and potentially additional mineralized lenses beyond the historically explored footprint. These are exploration hypotheses that now need to be validated systematically through mapping, geochemistry and drilling.”

Updated Montauban 3D geological model
Figure 2: Updated Montauban 3D geological model showing interpreted structural features derived from integrated geological, geochemical and ANT datasets.

Framework for 2027 Exploration Planning

The integrated 3D model is expected to serve as the technical foundation for ESGold’s next phase of exploration planning across the Montauban property. The Company expects follow-up work to proceed through a disciplined process of database validation, target ranking and targeted drilling and a summary of these steps is set out below:

Phase 1 — Database Validation and Target Refinement
ESGold intends to complete a formal audit and validation of the historical drillhole database while continuing to refine lithological and structural interpretations, integrate additional geochemical and geophysical information, improve the positioning of historical underground workings and maintain the 3D model as a version-controlled exploration platform.

Phase 2 — Property-Scale Target Ranking
Exploration targets will be ranked according to the coincidence of independent geological criteria, with priority given to areas where favourable stratigraphic/lithological position, structural architecture, Zn-Cu ± Ba-Ag geochemical responses and supporting geophysical observations occur together. Particular attention will be given to possible structural repetitions, folded or displaced favourable units, and stacked target geometries that could explain mineralization outside the historical mine footprint. This approach progressively reduces geological uncertainty before capital is committed to drilling.

Phase 3 — Targeted Drilling
Following target validation and ranking, ESGold intends to develop a targeted drilling program to test the highest-priority geological hypotheses generated from the integrated model. Initial drilling would focus on targets supported by multiple datasets, including selected opportunities within the southern and eastern corridors. Selected conceptual targets within the northern ANT-2 area may subsequently be evaluated where the combined geological, structural, geochemical and geophysical interpretation justifies drill testing. Results would be incorporated back into the 3D model to refine subsequent targeting.

A Dynamic Exploration Platform

Geomatic World Inc. completed the data integration, geological interpretation and 3D modelling, while CAUR Technologies Inc. completed the ANT survey and interpretation that provided the expanded geophysical framework. The resulting model functions as a dynamic exploration platform. As additional drilling, geological mapping, structural measurements, assay datasets and geochemical results become available, ESGold can update the model and reassess the relative priority of exploration targets.

Technical Disclosure

The 3D geological model described in this news release is an interpretive geological and exploration tool. It is not a mineral resource estimate, and the geological, geochemical or geophysical targets discussed in this release should not be interpreted as demonstrating the presence, grade, tonnage or continuity of mineralization. In particular, direct continuity of the known high-grade mineralized bodies into the northern ANT-2 area has not been demonstrated. Any future mineral resource-related application of the model will require appropriate database validation, geological and estimation domains, sufficient drilling and sampling, QA/QC procedures and independent technical review in accordance with applicable securities regulations.

Qualified Person
The scientific and technical information in this news release has been reviewed and approved by Merouane Rachidi, Ph.D., P.Geo., an independent Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About ESGold Corp.

ESGold Corp. (CSE: ESAU | OTCQB: ESAUF | FSE: Z7D) is a fully permitted, fully funded, pre-production mining company advancing a scalable clean mining model across North America. The Company’s flagship Montauban Gold-Silver Project in Quebec is under construction. With a dual-track strategy of cash flow today and discovery tomorrow, ESGold is building a platform for clean, sustainable growth and long-term shareholder value.

For more information, please contact ESGold Corp. at +1-888-370-1059 or visit esgold.com for additional resources, including a French version of this press release, past news releases, a 3D model of the Montauban processing plant, media interviews, and opinion-editorial pieces.

Stay connected by following us on X (formerly Twitter), LinkedIn, and joining our Telegram channel.

For further information on the Company please contact:
Email: ir@esgold.com or info@esgold.com or gordon@esgold.com
Phone: 604-885-1348 or 1-888-370-1059 or 250-217-2321

On behalf of the Board of Directors of ESGold Corp.

Gordon Robb

Chief Executive Officer & Director

Forward Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including statements regarding the ANT survey, the 3D model, and current and future exploration activities and potential. Forward-looking information is based on reasonable assumptions believed to be current but involves known and unknown risks and uncertainties that may cause actual results to differ materially. Historical data referenced herein is not current, has not been independently verified by ESGold, and should not be relied upon for investment decisions. ESGold disclaims any obligation to update or revise forward-looking information except as required by law.

These forward-looking statements reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include, among other things: a possible drill program and results therefrom and exploration activities at the Montauban Project, the ANT-based 3D geological model, its results and interpretation of the same, conditions in general economic and financial markets; accuracy of assay results; geological interpretations from drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; the historical basis for current estimates of potential quantities and grades of target zones; the availability of skilled labour and no labour related disruptions at any of the Company’s operations; no unplanned delays or interruptions in scheduled activities; all necessary permits, licenses and regulatory approvals for operations are received in a timely manner; the ability to secure and maintain title and ownership to properties and the surface rights necessary for operations; and the Company’s ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive. 

The Company cautions the reader that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements contained in this news release and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; general market and industry conditions; and those factors identified under the caption “Risk Factors” in the Company’s continuous disclosure documents filed on SEDAR+ at http://www.sedarplus.ca.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/9ac458ac-3762-4bb0-ad07-16e6596a88da

https://www.globenewswire.com/NewsRoom/AttachmentNg/07c4ccec-6e5a-4c5a-9654-a4a09d206b07

GREENWICH, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) — Stardust Power Inc. (NASDAQ: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today provided an update under its previously announced agreement with Oklahoma Gas and Electric Company (“OG&E”) relating to electrical infrastructure development for Stardust Power’s proposed lithium refinery in Muskogee, Oklahoma.

The agreement advances the development of critical electrical infrastructure. OG&E is securing long-lead electrical infrastructure required to support large-scale industrial power delivery to the refinery. As electrical infrastructure is typically one of the longest-lead and most critical components of large industrial developments, securing these items represents an important milestone.

“As we continue preparing the Muskogee site for future EPC activities, securing critical electrical infrastructure remains an important component of our overall strategy,” said Chris Celano, Chief Operating Officer of Stardust Power.

Stardust Power’s refinery site spans approximately 66 acres within the Southside Industrial Park in Muskogee, Oklahoma and, once at nameplate capacity, is expected to produce up to 50,000 metric tons per annum of battery-grade lithium carbonate. The refinery is being developed in two phases of approximately 25,000 metric tons per annum for each train.

About Stardust Power Inc.  

Stardust Power (NASDAQ: SDST) is building one of America’s largest battery-grade lithium carbonate refineries in Muskogee, Oklahoma, strategically located in the center of the United States’ growing energy and manufacturing corridor. The refinery is expected to have production capacity of up to 50,000 metric tons per annum and addresses the critical shortage of U.S. lithium refining capacity. Stardust Power is focused on building a resilient American battery supply chain.

For more information, visit www.stardust-power.com 

Stardust Power Contacts

For Investors:
Johanna Gonzalez
investor.relations@stardust-power.com

For Media:
Michael Thompson
media@stardust-power.com

Cautionary Note Regarding Forward-Looking Statements 

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects. These statements may include, without limitation, statements regarding management’s expectations about future business strategies, financial performance, operating results, growth opportunities, market developments, competitive position, regulatory outlook, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “model,” “outlook,” “plan,” “predict,” “project,” “seek,” “target,” “will,” “could,” “should,” or similar expressions.

Forward-looking statements are not guarantees of future performance. They are based on current expectations, estimates, forecasts, and assumptions that involve significant risks and uncertainties, many of which are beyond the Company’s control and are difficult to predict. Actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various factors, including but not limited to: macroeconomic conditions; inflationary pressures; changes in interest rates; supply chain disruptions; evolving consumer demand; competitive and technological developments; regulatory or legal changes; litigation exposure; cybersecurity threats; and fluctuations in foreign exchange rates. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any such forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Except as required by law, the Company assumes no obligation and expressly disclaims any duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, even if subsequent events cause expectations to change.

You should consult our filings with the U.S. Securities and Exchange Commission (SEC), including the “Risk Factors” section of its most recent Annual Report on Form 10-K and subsequent filings on Form 10-Q, for additional detail about the factors that could affect our financial and other results.

Recognition Underscores FTI Consulting and Compass Lexecon’s Global Expertise in Construction Advisory, Disputes, Digital Forensics, E-discovery, Forensic Accounting and Investigations

WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that the firm and its Compass Lexecon subsidiary led the Lexology Index Consulting Experts list for the eleventh consecutive year, with 127 professionals recognized globally.

The list identifies leading consulting experts through an independent research process that combines qualitative market feedback with quantitative analysis of relevant data points, including recommendations from corporate counsel, clients, law firms and other market participants. Professionals from FTI Consulting and Compass Lexecon were selected based on the breadth of expertise across construction advisory, E-discovery, digital forensics, financial advisory and valuation and forensic accounting.

Several FTI Consulting and Compass Lexecon professionals were also named Global Elite Thought Leaders, a distinction for experts considered in the top 5% of practitioners worldwide. Experts include: Mark Bezant, Carla Chavich, Craig Earnshaw, Renato Fazzone, Veeral Gosalia, Brett Harrison, Stefan Heissner, Basil Imburgia, Thierry Linares, Patrick McGeehin, Boaz Moselle, James Nicholson, Karl Payeur, Andrew Rhodes, Ian Smith and Dawna Wright.

FTI Consulting and Compass Lexecon professionals named to the 2026 list include the following:

Construction – Quantum, Delay & Technical – Experts

Construction – Quantum, Delay & Technical – Future Leaders

Digital & Data – Data and E-Discovery Experts

Digital & Data – Digital Forensic Experts

Financial Advisory and Valuation – Quantum of Damages – Experts

Financial Advisory and Valuation – Quantum of Damages – Future Leaders

  • Joel Franks, Managing Director – London
  • Nicolas Mocq, Senior Director – Paris
  • Andrew Preston, Senior Managing Director – Washington, D.C.
  • Tara Singh, Senior Managing Director – Toronto

Forensic Accountants – Experts

In addition to this recognition, Compass Lexecon recently topped the Lexology Index Competition 2026 list with the largest roster of featured consulting experts: 65 competition economists and future leaders were recognized globally. Nine FTI Consulting professionals were also recognized as competition economists on the list.

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at https://www.fticonsulting.com.

About Compass Lexecon
Compass Lexecon is internationally recognized as a leading economic consulting firm with preeminent competition, finance, intellectual property, international arbitration, and energy practices. With more than 600 professionals in 23 offices around the world, Compass Lexecon offers a global perspective on economic matters. For the past two decades, Compass Lexecon has been ranked as one of the leading antitrust economics firms in the world by the Global Competition Review. To learn more about Compass Lexecon or to find one of our professionals, please visit www.compasslexecon.com.

FTI Consulting, Inc.  
555 12th Street NW  
Washington, DC 20004  
+1.202.312.9100 

Investor Contact:  
Mollie Hawkes 
+1.617.747.1791 
mollie.hawkes@fticonsulting.com 

Media Contact:  
Sam Ford 
+1.617.480.7402
samantha.ford@fticonsulting.com

Statistically significant benefits observed in bezisterim-treated Long COVID patients 
in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise

Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population

An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options

Conference call scheduled for 8:30 a.m. today, September 15, 2026, to discuss results.

CARSON CITY, Nev., Sept. 15, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced topline results from the Company’s Phase 2 ADDRESS-LC trial (NCT06847191) evaluating its investigational drug candidate bezisterim, an oral drug that crosses the blood-brain barrier and is believed to reduce inflammation and improve insulin sensitivity, in Long COVID. In pre-specified subgroup analyses submitted to the FDA prior to data unblinding, patients with greater baseline burden on one or more symptoms (approximately 78% of trial participants) demonstrated statistically significant improvements on multiple clinically coherent endpoints. Bezisterim’s safety and tolerability profile was similar to placebo.

“I am excited by the findings in the ADDRESS-LC study. These results are among the most promising we have seen in this field so far and clearly warrant progressing to a confirmatory Phase III trial,” said Michael Peluso, MD, MHS, Associate Professor of Medicine, University of California, San Francisco.   “If bezisterim can truly help the patients with high symptomatic burden, that would be a significant benefit for the patient community”

“We have not seen anything like this from any other trial,” commented Ezra Spier, Long COVID patient advocate and ADDRESS-LC Patient Advisor. “We have not seen results that are this clear or compelling before, and this could have a significant impact for Long COVID patients.”

The ADDRESS-LC trial was a Phase 2, multicenter, randomized, double-blinded, placebo-controlled exploratory study that enrolled 203 patients to evaluate whether bezisterim could improve key neurological symptoms of Long COVID, including fatigue, brain fog, cognitive impairment and post-exertional malaise (PEM). The purpose of the Phase 2 trial was to identify the clinical endpoints where bezisterim may have the greatest effect and within which patient subpopulations. The ADDRESS-LC trial explored 22 different measures to assess clinical outcomes and a series of different biomarkers.

“The results suggest that bezisterim may help improve symptoms of fatigue, post‑exertional malaise, and cognitive impairments in patients with high symptom burden, which represents approximately 80% of patients who entered the trial. Patients who were not experiencing a meaningful symptom at the outset have little room to show improvement on that measure,” said Cuong Do, BioVie’s President and CEO. “Because fatigue, post‑exertional malaise, and cognitive dysfunction are defining features of the more severe and persistent Long COVID phenotypes1 described in RECOVER and other large cohort studies, we find it particularly encouraging that bezisterim demonstrated its strongest effects in patients experiencing these symptoms. To our knowledge, this is the first time a drug candidate has shown the ability to help patients improve across these persistent Long COVID symptoms.2 Thus, bezisterim may have the potential to become the first therapy for the neurological symptoms of Long COVID, if confirmed in our future Phase 3 trial.”

The enrolled patients were grouped into distinct symptom-severity segments based on baseline characteristics that were pre-specified in the Statistical Analysis Plan submitted to the FDA prior to unblinding; including patients with high severity of individual symptoms of fatigue, PEM and objective cognitive impairment, as well as those with two or more in combination. This wide spectrum of disease burden highlights the evolving understanding of the heterogeneity of the disease and the precision medicine approach needed to evaluate each patient segment with the most appropriate clinical endpoint.

Fig1 -- High Objective Cognitive Impairment

When the full Intent‑to‑Treat (ITT) population of 203 patients is evaluated without segmentation, bezisterim shows numerical trends favoring treatment over placebo across nearly all individual endpoints, as reflected in the Cohen’s d effect sizes. Cohen’s d quantifies the magnitude of difference between treatment and control groups, and a positive value indicates that the treatment effect was greater in the bezisterim arm than in the placebo arm. In this heterogenous ITT population, no individual endpoint reached statistical significance (p<0.05), likely because patients with low baseline symptom burden had little room to improve, which may have diluted the overall signal. Twenty-one of the 22 endpoints showed numerical trends favoring bezisterim.

Fig2 -- Cohen's D Effect Sizes

In pre-specified subgroup analyses, differential treatment effects emerged when focusing on patients with high baseline symptom burden. Despite reducing sample size (N), the treatment effect sizes more than doubled compared to the ITT population, as seen with higher Cohen’s d values, and the endpoints that reached statistical significance increased suggesting a coherent explanation for the clinical improvements. The most severe half of patients with fatigue symptoms showed statistically significant improvements on five endpoints (3 out of 5 of which are fatigue-specific), along with trends in post-exertional malaise and sleep. Patients with high post-exertional malaise experienced statistically significant improvements across malaise, fatigue, and objective cognitive measures. And patients who entered the trial with substantial objective cognitive impairment demonstrated statistically significant improvements on four clinically coherent objective cognitive endpoints. These subgroup findings are exploratory and require confirmation in an adequately powered prospective study. The summary “forest chart” chart below shows only those endpoints that reach statistically significant or are trending, and the charts for all endpoints can be found in the full data announcement presentation that will be discussed during today’s conference call.

Fig3 -- Pre-Specified Sub Group Cohen's D Effect Sizes

“I am super excited for the Long COVID community because of this data,” stated Grace McComsey, Professor of Medicine and infectious diseases researcher. “At Case Western Reserve University, we have been a part of almost every negative study so far. It’s great to see a trial showing such potential effectiveness while using a well-tolerated oral drug.”

“Research has demonstrated that Long COVID is not a single disease, but a complex and heterogeneous syndrome with multiple clinical and biological subtypes,” said Joseph Palumbo, MD, BioVie’s EVP of Research & Development and Chief Medical Officer. “A key challenge in clinical development is not only establishing efficacy but also identifying the patients most likely to benefit and understanding the drivers of that response. Consistent with observations from our other clinical programs, the ADDRESS-LC trial showed that patients with higher disease burden at baseline experienced the greatest and most rapid improvements with bezisterim treatment. These findings support an intuitive strategy for identifying the patients most likely to benefit from treatment, grounded in both clinical presentation and underlying biology. This approach has the potential to enhance clinical outcomes and guide the design of future registrational studies.”

Bezisterim’s safety and tolerability were similar to placebo. Overall, 41.6% of bezisterim patients experienced at least one treatment-emergent adverse event compared to 55.9% for placebo. The most frequently reported drug-related adverse event was headache, experienced by 4% of bezisterim-treated patients vs. 4.9% for placebo. No serious adverse events were reported in the bezisterim arm (vs. one in placebo). The safety findings are particularly important given the extensive concomitant medication use observed in the trial population.

Conference call to discuss results

BioVie management will host a conference call at 8:30 a.m. EDT today, September 15, 2026, to discuss the findings and results. A live Q&A session with management will follow the presentation.

To register for the conference call, please visit: https://lifescievents.com/event/bkvp81/

About Long COVID

An estimated 17-20 million U.S. adults reported to be living with Long COVID,4 with 3.8 million experiencing significant limitation to their daily lives.5 Almost 50 percent of those with Long COVID develop persistent or intermittent symptoms.6 The neurological and neuropsychiatric symptoms are among the most common and disabling manifestations of the condition and include fatigue, PEM, sleep disturbance, and persistent sense of difficulty with thinking and memory.7 Chronic innate inflammation accompanied by ongoing immune dysregulation is among the leading hypotheses proposed to explain the symptoms in Long COVID, with numerous investigators describing findings in Long COVID that appear to be supportive of the intended biological targets of bezisterim. Currently, there are no FDA-approved treatment options for Long-COVID.

About the ADDRESS-LC trial

The Phase 2 ADDRESS-LC study (NCT06847191), which is fully funded by a grant from the U.S. Department of War (DoW), is a randomized (1:1), placebo-controlled, signal-finding proof-of-concept, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with Long COVID who have cognitive impairment sequelae and fatigue. The study compared bezisterim, administered as a 20 mg oral capsule twice daily, with a matching placebo to assess its effects on neurocognitive and fatigue-related symptoms. The trial evaluated 22 clinical outcome measures, with no single endpoint pre-specified as the primary determinant of study success. Endpoints include assessing changes in overall clinical benefit, subjective and objective cognitive function, fatigue, sleep disturbance, Quality of Life and PEM. As a signal-finding study, the trial was designed to identify efficacy signals, measure treatment effect magnitude, and identify patient subgroups most likely to benefit, to inform the design of future Phase 3 trials

About Bezisterim

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease (PD), Long COVID (LC), and Alzheimer’s disease (AD).

In PD, BioVie completed the SUNRISE-PD trial, which enrolled 57 patients to establish proof of mechanism and proof of concept in individuals with early-stage disease who had not previously been treated with carbidopa/levodopa. Topline results showed that patients treated with bezisterim experienced improvements with blood-based markers of inflammation, as well as a broad range of biomarkers associated with cellular health and neuronal integrity. Clinically, patients treated with bezisterim demonstrated greater improvements than those receiving placebo across multiple measures of daily functioning, motor symptoms, and non-motor symptoms.

For LC, the ADDRESS-LC trial enrolled approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with LC. The hypothesis being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate).

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.

Terms of the U.S. Department of War (DoW) Award

The work is supported by the Assistant Secretary of War for Health Affairs and endorsed by the DoW by a fully funded award in the amount of $13.13 million through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations in this press release are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the DoW.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” “potential,” “may,” or words of similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim to address unmet clinical needs in Long COVID and Parkinson’s disease; the design and conduct of future clinical trials, including a potentially pivotal Phase 3 trial; the potential clinical significance of subgroup analyses and biomarker observations; and the Company’s ability to advance bezisterim through clinical development. The clinical endpoints reported in this release are exploratory in nature. The Phase 2 ADDRESS-LC trial did not achieve statistical significance on any endpoint in the overall intent-to-treat population; statistically significant results were observed only in pre-specified subgroup analyses. Subgroup analyses are hypothesis-generating and may not be replicated in future trials. Changes in biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these endpoints as surrogate endpoints for Long COVID. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates, the possibility that results observed in this Phase 2 study of 203 patients may not be replicated in larger or longer-duration trials, the exploratory nature of subgroup analyses, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries:
        
Contact:
Chuck Padala
Managing Director, LifeSci Advisors, LLC
chuck@lifesciadvisors.com

For Media Inquiries:
        
Contact:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com

1 Geng L, et al. JAMA. 2025;333(8):694–700. doi:10.1001/jama.2024.24184
2 Eight Phase 2 clinical trials have been conducted by various organizations to assess 13 interventions in Long COVID. None of the interventions have demonstrated benefit thus far. Source: https://recovercovid.org/funding
3 Objective cognitive assessments are conducted using an iPad that gives patients tasks to complete and measure the person’s actual cognitive performance.
4 U.S. Department of Health and Human Services (https://www.hhs.gov/longcovid/index.html)
5 Bonuck et al. Commun Med. 2026;6:177. doi:10.1038/s43856-026-01516-7.
6 Thaweethai et al. Nat Commun. 2025;16(1):9557. doi:10.1038/s41467-025-65239-4.
7 Geng et al. JAMA. 2025 Feb 25;333(8):694-700. doi: 10.1001/jama.2024.24184.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a305c2ae-97bb-466a-b843-541cb0eb7598
https://www.globenewswire.com/NewsRoom/AttachmentNg/f3710d26-092a-4d5f-8170-4265c9cfb673
https://www.globenewswire.com/NewsRoom/AttachmentNg/b8325cd1-e936-4e15-a18e-271e929be6b2 

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce that Aras Azadian, CEO of Avicanna Inc. and Avicanna Inc. will be presenting live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.

Avicanna Participates in Virtual Conference OTC Markets Press Release Sept 26

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. Avicanna’s CEO Aras Azadian will be presenting on Sep 17th at 10:30 am Eastern Time.

A re-play of the webcast will be available following the conclusion of the conference.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

To learn more about the event, please click the link at www.virtualinvestorconferences.com.

To register for the event, please click the registration link at REGISTER HERE

About Avicanna Inc 
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. 

  • Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. 
  • Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. 
  • Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. 
  • Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit our website or contact Ivana Maric by email at ir@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements 

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2026, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d6d26ce5-ef7f-4efd-b5c1-f032a8d43399

Xcelsior CNG 60-Foot

ST. CLOUD, Minn., Sept. 15, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, subsidiary New Flyer of America Inc. (New Flyer), today announced it has been awarded a contract from the Central Ohio Transit Authority (COTA) for up to 45 sixty-foot Xcelsior® compressed natural gas (CNG) heavy-duty transit buses (90 equivalent units, or EUs).

The contract includes a firm order of 12 buses, with options for COTA to purchase up to 33 additional buses. The firm order will be added to New Flyer’s third quarter 2026 backlog, while the option buses will be added to the company’s option backlog.

The articulated Xcelsior CNG buses will replace end-of-life vehicles while supporting the launch of a new bus rapid transit (BRT) service in Columbus and surrounding communities. The purchase is supported by funding awarded through the Low or No Emission (Low-No) Grant Program, following New Flyer and COTA’s successful 2025 collaboration to secure funding for articulated CNG buses.

New Flyer has partnered with COTA since 2000, delivering more than 230 buses, including 102 CNG-powered buses. This latest award represents a new milestone in that relationship, marking COTA’s first purchase of 60-foot New Flyer articulated buses as the agency expands high-capacity transit service across Central Ohio.

“Bus rapid transit is transforming the way communities move, providing greater capacity and an enhanced passenger experience while supporting regional growth,” said Chris Stoddart, President, North American Bus and Coach, NFI. “Delivering COTA’s first 60-foot New Flyer articulated buses is an exciting milestone that reflects the agency’s vision for high-capacity transit and our shared commitment to supporting the future of mobility in central Ohio.”

“The addition of articulated buses to our fleet is another important step toward building the rapid transit system Central Ohio needs and deserves,” said Monica Tellez-Fowler, COTA President/CEO. “As our region continues to grow, we must invest in the capacity, infrastructure, and service needed to move more people efficiently and reliably. These vehicles will help us deliver on the promise of LinkUS and bring high-capacity rapid transit closer to reality for our customers and communities.”

Launched in 1974, COTA is the regional public transit authority serving the greater Columbus metropolitan area. Today, the agency provides fixed-route bus, bus rapid transit, paratransit, and microtransit services across the greater Columbus and Central Ohio area, serving approximately 1.3 million residents. COTA’s network carries more than 12 million passenger trips annually and continues to expand service to meet the transportation needs of one of the fastest-growing regions in the United States.

With the addition of New Flyer’s 60-foot Xcelsior CNG buses, COTA will further strengthen its investment in high-capacity transit designed to improve mobility, support regional growth, and enhance the customer experience along its BRT corridors.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer® (heavy-duty transit buses), MCI® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

About New Flyer

New Flyer is North America’s heavy-duty transit bus leader and offers the most advanced product line under the Xcelsior® and Xcelsior CHARGE® brands. It also offers infrastructure development through NFI Infrastructure Solutions™, a service dedicated to providing safe, sustainable, and reliable charging and mobility solutions. New Flyer actively supports over 35,000 heavy-duty transit buses (New Flyer, NABI, and Orion) currently in service, of which 8,600 are powered by electric motors and battery propulsion, and 1,900 are zero-emission. Further information is available at www.newflyer.com.

Forward-Looking Statements

This press release may contain forward-looking statements relating to expected future events and financial and operating results of NFI that involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures) and economic conditions of and funding availability for customers to purchase buses and to purchase parts or services (including as a result of recent U.S. policy developments); customers may not exercise options to purchase additional buses; the ability of customers to suspend or terminate contracts for convenience; production may be delayed or production rates may be decreased as a result of ongoing and future supply chain disruptions and shortages of parts and components, shipping and freight delays, and disruption to and shortage of labor supply; and the other risks and uncertainties discussed in the materials filed with the Canadian securities regulatory authorities and available on SEDAR at www.sedarplus.ca.  

Due to the potential impact of these factors, NFI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. 

For media inquiries, please contact: 
Melissa Schnee 
P: 385.910.6861 
Melissa_Schnee@newflyer.com 

For investor inquiries, please contact: 
Stephen King 
P: 204.792.1300 
Stephen.King@nfigroup.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/28f23adb-4e73-4d90-86a5-64ba54d842d4

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX) announced today that a quarterly dividend of $0.003036 per common share (“Common Share”) ‎will be payable on ‎October 15, 2026 to shareholders of record on September 29, 2026, with an ex-dividend ‎date of September 29, 2026. This dividend has been designated as an “eligible dividend” for Canadian ‎income tax ‎purposes.‎ ‎

About StorageVault Canada Inc.
StorageVault currently owns and operates 275 storage locations across Canada. StorageVault owns 243 of these locations plus over 5,000 portable storage units representing over 13.8 million rentable square feet on 802 acres of land. StorageVault also provides last mile storage and logistics’ solutions and professional records management services, such as document and media storage, imaging and shredding services.‎‎‎

For further information, contact Mr. Steven Scott or Mr. Iqbal Khan:

Tel: 1-877-622-0205
ir@storagevaultcanada.com

Follow us:
Instagram: @accessstorageca @depotiumminientrepot @sentinelstorageca @cubeitportablestorage
Facebook: /AccessStorageCA /Depotium /SentinelStorageCanada /Cubeit /FlexSpaceLogistics

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.